Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19146546 | 0.91 | KMT2A (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16090934 | 0.91 | KMT2A (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20385969 | 0.89 | KMT2A (0.42) | ALDH1A1NFE2L2SMN1; SMN2 | |
| SCHEMBL19146933 | 0.89 | KMT2A (0.42) | ALDH1A1NFE2L2SMN1; SMN2 | |
| SCHEMBL17695800 | 0.83 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16093641 | 0.83 | POLB (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL26972369 | 0.83 | POLB (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL402936 | 0.83 | POLB (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16090972 | 0.82 | NFE2L2 (0.35) | LMNAALDH1A1NFE2L2KEAP1HCAR2 | |
| SCHEMBL16090933 | 0.82 | ALDH1A1 (0.41) | ALDH1A1NFE2L2KEAP1HCAR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-08-10 | — | — | US | disclosed |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-11-12 | — | — | US | disclosed |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | LMNA 2354/4885ALDH1A1 363/4885NFE2L2 416/4885 |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | LMNA 2354/4885ALDH1A1 363/4885NFE2L2 416/4885 |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | LMNA 2354/4885ALDH1A1 363/4885NFE2L2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.